Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation

• Shady Adnan Awad,
• Oscar Brück,
• Naranie Shanmuganathan,
• Timo Jarvinen,
• Hanna Lähteenmäki,
• Jay Klievink,
• Hazem Ibrahim,
• Soili Kytölä,
• Perttu Koskenvesa,
• Timothy P. Hughes,
• Susan Branford,
• Matti Kankainen,
• Satu Mustjoki

Affiliations

Shady Adnan Awad

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center

Oscar Brück

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center

Naranie Shanmuganathan

Department of Haematology, Royal Adelaide Hospital and SA Pathology

Timo Jarvinen

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center

Hanna Lähteenmäki

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center

Jay Klievink

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center

Hazem Ibrahim

Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki

Soili Kytölä

HUS Diagnostic Center, HUSLAB, Helsinki University Hospital, University of Helsinki

Perttu Koskenvesa

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center

Timothy P. Hughes

Department of Haematology, Royal Adelaide Hospital and SA Pathology

Susan Branford

Department of Genetics and Molecular Pathology and Centre for Cancer Biology, SA Pathology

Matti Kankainen

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center

Satu Mustjoki

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center